{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:52:22Z","timestamp":1735584742483},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2020,9,28]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>CYP1A1 and CYP2D6 are both xenobiotic metabolizing enzymes belonging\nto the CYP450 enzyme family. Polymorphisms in these genes vary between individuals, resulting\nin dissimilar patterns of susceptibility to the effects of carcinogenic substances and drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In a prospective study, the influence of CYP1A1*2C and CYP2D6*4 gene polymorphisms\non the susceptibility to chronic myelocytic leukaemia (CML) were investigated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Prevalence of CYP1A1*2C and CYP2D6*4 was detected in blood specimens from three\nhundred participants - two hundred patients and a hundred healthy individuals as a control group, using\nPCR-RFLP.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>CYP1A1 Ile\/Val and Val\/Val genotype frequency in our study population was 82% &amp; 15%\nin CML patients and 55% &amp; 8% in controls, respectively. This suggests that carriers had an elevated\nrisk (OR=18.38, 95% CI=7.364-45.913, p value; =0.000 and OR=23.125,95 % CI=7.228-73.980, p\nvalue=0.000, respectively). Individuals carrying the CYP2D6 heterozygous genotype (IM) were notably\nfewer in number within the CML group at 43.5%, as opposed to 93% of the controls. This suggests\nthat the IM genotype may have a prophylactic function in lowering CML risk (OR=0.036, 95%\nCI=0.005-0.271, p value =0.001). In spite of the distribution of the homozygous mutant (PM) genotype\nbeing higher in cases with CML (87% as opposed to 6% in the control), this difference was\ndeemed non-significant (OR=0.558, 95% CI=0.064-4.845, p value =0.597).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These findings indicate that polymorphic CYP1A1 and CYP2D6 genes affect the susceptibility\nto CML.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163817666200518081356","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T08:16:00Z","timestamp":1589789760000},"page":"675-680","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia"],"prefix":"10.2174","volume":"20","author":[{"given":"Hadeil M.E.","family":"Idris","sequence":"first","affiliation":[{"name":"Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba B.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Mills","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth PO1 2UP, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abozer Y.","family":"Elderdery","sequence":"additional","affiliation":[{"name":"Faculty of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"43","volume":"1","author":"Sailaja K.","year":"2007","unstructured":"Sailaja K.; Vishnupriya S.; Surekha D.; Rao D.N.; Rao D.; Association of CYP2D6* 4 polymorphism with chronic myeloid leukemia. JMSR 2007,1(1),43-46","journal-title":"JMSR"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s40064-015-0966-y","volume":"4","author":"Kassogue Y.","year":"2015","unstructured":"Kassogue Y.; Dehbi H.; Quachouh M.; Quessar A.; Benchekroun S.; Nadifi S.; Association of glutathione S-transferase (GSTM1 and GSTT1) genes with chronic myeloid leukemia. Springerplus 2015,4(1),210","journal-title":"Springerplus"},{"key":"ref=3","first-page":"262","volume":"1","author":"Dhaval K.","year":"2016","unstructured":"Dhaval K.; Patel, D. J. S. Xenobiotics: An essential precursor for living system. Am J Adv Drug Deliv 2016,1(3),262-270","journal-title":"Am J Adv Drug Deliv"},{"key":"ref=4","first-page":"510","volume":"17","author":"Lakkireddy S.","year":"2015","unstructured":"Lakkireddy S.; Aula S.; Avn S.; Kapley A.; Rao Digumarti R.; Jamil K.; Association of the common CYP1A1*2C variant (Ile462Val Polymorphism) with chronic myeloid leukemia (CML) in patients undergoing imatinib therapy. Cell J 2015,17(3),510-519","journal-title":"Cell J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.2147\/OTT.S92259","volume":"8","author":"Lu J.","year":"2015","unstructured":"Lu J.; Zhao Q.; Zhai Y.J.; He H.R.; Yang L.H.; Gao F.; Zhou R.S.; Zheng J.; Ma X.C.; Genetic polymorphisms of CYP1A1 and risk of leukemia: A meta-analysis. OncoTargets Ther 2015,8,2883-2902","journal-title":"OncoTargets Ther"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2019-129655","volume":"134","author":"Mukry S.N.","year":"2019","unstructured":"Mukry S.N.; Shahni A.; Zaidi U.; Shamsi T.S.; Cytochromes P450 and glutathione S-transferases polymorphisms: Can they predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia? Blood 2019,134(Suppl. 1),5920","journal-title":"Blood"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/CEJ.0b013e3282b72093","volume":"17","author":"Chen H.C.","year":"2008","unstructured":"Chen H.C.; Hu W.X.; Liu Q.X.; Li W.K.; Chen F.Z.; Rao Z.Z.; Liu X.F.; Luo Y.P.; Cao Y.F.; Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur J Cancer Prev 2008,17(3),251-258","journal-title":"Eur J Cancer Prev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2174\/138920111795470994","volume":"12","author":"Stejskalova L.","year":"2011","unstructured":"Stejskalova L.; Pavek P.; The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol 2011,12(5),715-730","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41021-016-0066-4","volume":"39","author":"Ezzeldin N.","year":"2017","unstructured":"Ezzeldin N.; El-Lebedy D.; Darwish A.; El-Bastawisy A.; Hassan M.; Abd El-Aziz S.; Abdel-Hamid M.; Saad-Hussein A.; Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer. Genes Environ 2017,39(1),7-15","journal-title":"Genes Environ"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3748\/wjg.v10.i23.3389","volume":"10","author":"Abbas A.","year":"2004","unstructured":"Abbas A.; Delvinquiere K.; Lechevrel M.; Lebailly P.; Gauduchon P.; Launoy G.; Sichel F.; GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: Different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol 2004,10(23),3389-3393","journal-title":"World J Gastroenterol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12032-014-0889-4","volume":"31","author":"Al-Achkar W.","year":"2014","unstructured":"Al-Achkar W.; Azeiz G.; Moassass F.; Wafa A.; Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population. Med Oncol 2014,31(5),889","journal-title":"Med Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0019-5359.49077","volume":"63","author":"Surekha D.","year":"2009","unstructured":"Surekha D.; Sailaja K.; Rao D.N.; Padma T.; Raghunadharao D.; Vishnupriya S.; Association of CYP1A1*2 polymorphisms with breast cancer risk: A case control study. Indian J Med Sci 2009,63(1),13-20","journal-title":"Indian J Med Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pbc.20074","volume":"43","author":"Joseph T.","year":"2004","unstructured":"Joseph T.; Kusumakumary P.; Chacko P.; Abraham A.; Radhakrishna Pillai M.; Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004,43(5),560-567","journal-title":"Pediatr Blood Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"Zanger U.M.","year":"2013","unstructured":"Zanger U.M.; Schwab M.; Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013,138(1),103-141","journal-title":"Pharmacol Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"Wilkinson G.R.","year":"2005","unstructured":"Wilkinson G.R.; Drug metabolism and variability among patients in drug response. N Engl J Med 2005,352(21),2211-2221","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejphar.2013.12.025","volume":"724","author":"Wang X.","year":"2014","unstructured":"Wang X.; Li J.; Dong G.; Yue J.; The endogenous substrates of brain CYP2D. Eur J Pharmacol 2014,724,211-218","journal-title":"Eur J Pharmacol"},{"key":"ref=17","first-page":"49","volume":"4","author":"Surekha D.","year":"2010","unstructured":"Surekha D.; Sailaja K.; Rao D.N.; Padma T.; Raghunadharao D.; and Vishnupriya S.; CYP2D6*4 polymorphisms and breast cancer risk. Biol Med (Aligarh) 2010,4(2),49-55","journal-title":"Biol Med (Aligarh)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"Zhou S.F.","year":"2009","unstructured":"Zhou S.F.; Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009,48(12),761-804","journal-title":"Clin Pharmacokinet"},{"key":"ref=19","first-page":"339","volume":"18","author":"Gomes L.","year":"2005","unstructured":"Gomes L.; Lemos M.C.; Paiva I.; Ribeiro C.; Carvalheiro M.; Regateiro F.J.; CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 2005,18(5),339-343","journal-title":"Acta Med Port"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41021-017-0078-8","volume":"39","year":"2017","unstructured":"Anwarullah; Aslam, M.; Badshah, M.; Abbasi, R.; Sultan, A.; Khan, K.; Ahmad, N.; von Engelhardt, J. Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson\u2019s disease: A case control study. Genes Environ 2017,39(1),18-24","journal-title":"Genes Environ"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"Lee J.Y.","year":"2016","unstructured":"Lee J.Y.; Vinayagamoorthy N.; Han K.; Kwok S.K.; Ju J.H.; Park K.S.; Jung S.H.; Park S.W.; Chung Y.J.; Park S.H.; Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2016,68(1),184-190","journal-title":"Arthritis Rheumatol"},{"key":"ref=22","first-page":"12","volume":"138","author":"Taspinar M.","year":"2008","unstructured":"Taspinar M.; Aydos S.E.; Comez O.; Elhan A.H.; Karabulut H.G.; Sunguroglu A.; CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med Wkly 2008,138(1-2),12-17","journal-title":"Swiss Med Wkly"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7326\/M16-1107","volume":"166","author":"Shahab L.","year":"2017","unstructured":"Shahab L.; Goniewicz M.L.; Blount B.C.; Brown J.; McNeill A.; Alwis K.U.; Feng J.; Wang L.; West R.; Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: A cross-sectional study. Ann Intern Med 2017,166(6),390-400","journal-title":"Ann Intern Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1248\/bpb.25.383","volume":"25","author":"Nagai F.","year":"2002","unstructured":"Nagai F.; Hiyoshi Y.; Sugimachi K.; Tamura H.O.; Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull 2002,25(3),383-385","journal-title":"Biol Pharm Bull"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1309\/LM337JWOSVNEHPUI","volume":"42","author":"Farnaz Razmkhah Vahid Pazhakh","year":"2011","unstructured":"Farnaz Razmkhah Vahid Pazhakh; Farhad Zaker.; Farzaneh Atashrazm.; Maryam Sheikhi.; Frequency of CYP1A1*2C polymorphism in patients with leukemia in the iranian population. Lab Med 2011,42(4),220-223","journal-title":"Lab Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.canep.2010.05.002","volume":"34","author":"Sabitha K.","year":"2010","unstructured":"Sabitha K.; Reddy M.V.; Jamil K.; Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol 2010,34(5),587-592","journal-title":"Cancer Epidemiol"},{"key":"ref=27","first-page":"1360","volume":"46","author":"Ovsepian V.A.","year":"2010","unstructured":"Ovsepian V.A.; Vinogradova E.Iu.; Sherstneva E.S.; Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika 2010,46(10),1360-1362","journal-title":"Genetika"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2407-8-109","volume":"8","author":"Khedhaier A.","year":"2008","unstructured":"Khedhaier A.; Hassen E.; Bouaouina N.; Gabbouj S.; Ahmed S.B.; Chouchane L.; Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 2008,8,109","journal-title":"BMC Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2265.2007.02858.x","volume":"67","author":"Lemos M.C.","year":"2007","unstructured":"Lemos M.C.; Carrilho F.; Rodrigues F.; Coutinho E.; Gomes L.; Carvalheiro M.; Regateiro F.J.; Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf) 2007,67(2),180-183","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/carcin\/13.6.1035","volume":"13","author":"Wolf C.R.","year":"1992","unstructured":"Wolf C.R.; Smith C.A.; Gough A.C.; Moss J.E.; Vallis K.A.; Howard G.; Carey F.J.; Mills K.; McNee W.; Carmichael J.; Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992,13(6),1035-1038","journal-title":"Carcinogenesis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/carcin\/20.7.1225","volume":"20","author":"Lemos M.C.","year":"1999","unstructured":"Lemos M.C.; Cabrita F.J.; Silva H.A.; Vivan M.; Pl\u00e1cido F.; Regateiro F.J.; Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999,20(7),1225-1229","journal-title":"Carcinogenesis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/00008571-200010000-00004","volume":"10","author":"Roddam P.L.","year":"2000","unstructured":"Roddam P.L.; Rollinson S.; Kane E.; Roman E.; Moorman A.; Cartwright R.; Morgan G.J.; Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 2000,10(7),605-615","journal-title":"Pharmacogenetics"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182058\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:09:01Z","timestamp":1613714941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182058\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163817666200518081356","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}